A Chinese medicine composition and Chinese medicine preparation for lowering uric acid, and preparation method and application thereof

Abstract

The present invention relates to the technical field of traditional Chinese medicine, and discloses a Chinese medicine composition and Chinese medicine preparation for lowering uric acid, as well as a preparation method and application thereof. The Chinese medicine composition is mainly prepared from the following raw materials in parts by weight: 5-15 parts of Gastrodia elata, 1-5 parts of Panax notoginseng, 5-15 parts of lotus seed core, and 10-40 parts of corn silk. The preparation method of the Chinese medicine composition comprises: S1: mixing the raw materials and soaking them in water; S2: after steaming, filtering to obtain an extract; S3: steaming again and filtering to obtain an extract; S4: combining the extracts obtained by steaming twice and standing; S5: filtering, and concentrating the filtrate by vacuum distillation to prepare the Chinese medicine composition for lowering uric acid. The Chinese medicine composition can effectively reduce the level of blood uric acid, increase the expression of uric acid excretion transporter ABCG2, inhibit the activity of XOD in the liver, and has good safety and liver and kidney protection effects, and can be effectively used to treat hyperuricemia, and help control the occurrence and development of gout.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine, and more specifically, to a uric acid-lowering Chinese medicine composition and Chinese medicine preparation, and a preparation method and application thereof. Background Art

[0002] Hyperuricemia, commonly known as gout, is a disease caused by abnormal uric acid metabolism and excessive uric acid levels in the blood. The occurrence of this disease is related to purine metabolism. Under normal circumstances, purine in the human body is metabolized into uric acid and excreted from the body by the kidneys. When purine metabolism is abnormal or the kidney's uric acid excretion function decreases, the blood uric acid concentration will increase. Long-term hyperuricemia may lead to the formation of tophi, which are deposited in joints or soft tissues, causing clinical symptoms such as arthritis and kidney stones.

[0003] Traditional Western medicine treatment of hyperuricemia and gout mainly relies on nonsteroidal anti-inflammatory drugs, uric acid production inhibitors (such as allopurinol) and uric acid excretion promoters (such as benzbromarone). However, long-term use of these drugs may be accompanied by a variety of adverse reactions, such as liver and kidney damage, water and salt metabolism disorders (hyponatremia, hypokalemia, etc.), and some patients may not be able to use these drugs due to drug allergies, renal insufficiency and other reasons.

[0004] In traditional Chinese medicine, according to TCM theory, "gout" belongs to the category of "arthralgia", which is believed to be mainly caused by pathogenic factors such as dampness, heat, wind, and blood stasis. TCM treatment of gout focuses on harmonizing yin and yang, improving qi and blood, removing wind and dampness, and clearing away heat and detoxification. In recent years, with the widespread application of TCM at home and abroad, the use of TCM compositions to treat hyperuricemia and gout has gradually become a new treatment idea. TCM compositions can effectively reduce blood uric acid and alleviate the symptoms of gout patients through the effects of multiple components, multiple pathways, and multiple targets. They have the advantages of high safety, few side effects, and a wide range of applications.

[0005] Although traditional Chinese medicine has shown potential in the treatment of hyperuricemia, its mechanism of action, effective ingredients and their interactions are still not fully understood due to the complex composition of traditional Chinese medicine. Therefore, developing a safe, effective and well-defined traditional Chinese medicine composition for the treatment of hyperuricemia is a hot topic and difficulty in current research.

[0006] As shown in the prior art CN104383363B, CN113813342A, and CN116492428A, many Chinese medicine compositions contain a large number of ingredients, which not only increases the complexity of the preparation process, but also may affect the stability of the drug and the patient's tolerance. Complex ingredients may also increase the cost of the drug, making it difficult for patients to afford it. In addition, some medicinal materials such as cattle bone marrow and tadpoles are not only difficult to obtain, but may also face ethical and legal challenges in modern society. Although most Chinese medicine compositions claim to be able to treat gout, few solutions can clearly target the core problem of gout, namely hyperuricemia. This means that existing treatment options may have a certain effect in relieving symptoms, but have limited effects in fundamentally reducing blood uric acid levels and preventing gout recurrence. With the deepening of the understanding of the safety of Chinese medicine ingredients, the potential toxicity and side effects of some traditional ingredients have gradually been revealed. This requires a strict safety assessment of existing Chinese medicine compositions and the development of new treatment options that are both effective and safe.

[0007] In view of the above problems, a safe and long-term treatment method for lowering uric acid levels is urgently needed. In traditional Chinese medicine, many herbs are used to treat various diseases, including hyperuricemia, due to their unique efficacy and low side effects. However, how to scientifically combine these herbs to improve their uric acid-lowering effect and reduce side effects is the focus of current research. Summary of the invention

[0008] The present invention provides a uric acid-lowering Chinese medicine composition to overcome the defects of the Chinese medicine composition described in the prior art, such as complex ingredients, difficulty in obtaining, low safety, and inability to directly treat hyperuricemia.

[0009] Another object of the present invention is to provide a method for preparing a uric acid-lowering Chinese medicine composition

[0010] Another object of the present invention is to provide an application of a uric acid-lowering Chinese medicine composition;

[0011] Another object of the present invention is to provide a uric acid-lowering drug.

[0012] In order to solve the above technical problems, the technical solution of the present invention is as follows:

[0013] A uric acid-lowering Chinese medicinal composition is mainly prepared from the following raw materials in parts by weight: 5-15 parts of gastrodia elata, 1-5 parts of panax notoginseng, 5-15 parts of lotus seed core, and 10-40 parts of corn silk.

[0014] Preferably, 8-12 parts of Gastrodia elata, 2-4 parts of Panax notoginseng, 8-12 parts of lotus seed core, and 20-35 parts of corn silk.

[0015] Preferably, 9 parts of Gastrodia elata, 3 parts of Panax notoginseng, 9 parts of lotus seed core, and 30 parts of corn silk.

[0016] Furthermore, the weight ratio of the Gastrodia elata to Panax notoginseng is 1-5:1, and the weight ratio of the lotus seed core to corn silk is 1:2-8.

[0017] Preferably, the weight ratio of Gastrodia elata to Panax notoginseng is 3-5:1, and the weight ratio of lotus seed core to corn silk is 1:2-4.

[0018] Preferably, the weight ratio of Gastrodia elata to Panax notoginseng is 3:1, and the weight ratio of lotus seed core to corn silk is 3:10.

[0019] A method for preparing the uric acid-lowering Chinese medicine composition comprises the following steps:

[0020] S1: Mix Gastrodia elata, Panax notoginseng, lotus seed core and corn silk and soak them in water;

[0021] S2: After steaming, filter to obtain the extract;

[0022] S3: adding water and boiling again, filtering to obtain the extract;

[0023] S4: combining the extracts obtained from the two steamings and allowing to stand;

[0024] S5: filtering, and concentrating the filtrate by vacuum distillation to obtain the uric acid-lowering Chinese medicine composition.

[0025] Furthermore, the amount of water added in S1 and S3 is 8 to 30 times the total weight of Gastrodia elata, Panax notoginseng, lotus seed core and corn silk.

[0026] Preferably, the amount of water added to S1 and S3 is 20 times the total weight of Gastrodia elata, Panax notoginseng, lotus seed core and corn silk.

[0027] Furthermore, the soaking time in S1 is greater than 0.5h.

[0028] Preferably, the soaking time in S1 is 0.5h.

[0029] Furthermore, the cooking time in S2 is greater than 0.5h.

[0030] Optionally, the cooking time in S2 is 0.5h.

[0031] Furthermore, the cooking time in S3 is greater than 20 minutes.

[0032] Preferably, the cooking time in S3 is 20 minutes.

[0033] An application of the uric acid-lowering Chinese medicine composition is used for preparing a uric acid-lowering medicine.

[0034] A uric acid-lowering medicine is prepared from the uric acid-lowering traditional Chinese medicine composition.

[0035] Furthermore, the medicine is an oral preparation, including tablets, capsules, oral liquids, syrups, extracts, and mixtures.

[0036] Preferably, after S5 is concentrated, the active ingredients of the traditional Chinese medicine composition are obtained, and after adding auxiliary materials, the uric acid-lowering drug is prepared.

[0037] Preferably, the auxiliary materials added to prepare the tablets include at least one of a diluent, a wetting agent, a binder, a disintegrant, and a lubricant.

[0038] Preferably, the auxiliary materials added to prepare the capsules include at least one of a diluent, a wetting agent, a binder, a disintegrant, and a lubricant.

[0039] Preferably, the auxiliary materials added to prepare the syrup include at least one of a flavoring agent, a preservative, and a solubilizing agent.

[0040] Preferably, the auxiliary materials added to prepare the mixture include at least one of a flavoring agent and a preservative.

[0041] Preferably, the auxiliary materials added to prepare the oral solution include at least one of a flavoring agent, a preservative, and a solubilizing agent.

[0042] The medicinal properties of the Chinese medicine of the present invention are as follows:

[0043] Gastrodia elata: neutral in nature, sweet in taste. Enters the liver meridian. Soothes the liver, calms wind and stops spasms.

[0044] Panax notoginseng: warm in nature, sweet and slightly bitter in taste. Enters the liver and stomach meridians. Disperses blood stasis, stops bleeding, reduces swelling and relieves pain.

[0045] Lotus seed heart: cold in nature, bitter in taste. Enters the kidney meridian and heart meridian. Clears the heart and calms the mind, connects the heart and kidney, astringes semen and stops bleeding.

[0046] Corn silk: neutral in nature, sweet in taste. Enters the kidney meridian, stomach meridian, liver meridian, and gallbladder meridian. Diuretic, swelling-reducing, blood pressure-lowering, diuretic and dampness-removing.

[0047] The innovative Chinese medicine composition of the present invention emphasizes the importance of each component. Each component may work together to reduce uric acid levels through different mechanisms, such as directly reducing XOD activity, increasing uric acid excretion, or affecting other related metabolic pathways. The lack of any one component will reduce the overall effect of the composition, indicating that there may be a synergistic effect between these components, which jointly promotes the reduction of uric acid levels and the treatment of hyperuricemia. The Chinese medicine composition of the present invention highlights the advantages of the concept of Chinese medicine compound prescriptions. Not only does each component play its role, but the therapeutic effect of the Chinese medicine composition is also improved through the interaction of multiple components.

[0048] Compared with the prior art, the technical solution of the present invention has the following beneficial effects:

[0049] 1. Effectively reduce blood uric acid levels: The Chinese medicine composition preparation of the present invention can significantly reduce the blood uric acid level of hyperuricemia model mice, and the blood uric acid level is reduced by 81.53% after administration. This shows that the Chinese medicine composition of the present invention can be effectively used to treat hyperuricemia and help control the occurrence and development of gout.

[0050] 2. Increase the expression of ABCG2, a uric acid excretion transporter: The Chinese medicine composition preparation of the present invention can significantly increase the expression of ABCG2, a uric acid excretion transporter in the kidney. The mRNA expression level of ABCG2 increased by 41.09% compared with the model group. The Chinese medicine composition preparation of the present invention can promote the excretion of uric acid, further proving that the Chinese medicine composition can reduce the blood uric acid level by promoting the excretion of uric acid.

[0051] 3. Inhibition of XOD activity in the liver: The Chinese medicine composition preparation of the present invention can effectively inhibit the activity of xanthine oxidase (XOD) in the liver, which is reduced by 17.34% compared with the model group, reducing the production of uric acid. XOD is a key enzyme in the process of uric acid production, and the inhibition of its activity helps to reduce the level of uric acid in the blood.

[0052] 4. Good safety and liver and kidney protection: The Chinese medicine composition preparation of the present invention has no obvious toxic damage to the liver and kidney tissues of mice, but shows a protective effect on these organs, especially at high doses. The levels of blood urea nitrogen, blood creatinine, alanine aminotransferase, and aspartate aminotransferase were reduced by 64.25%, 30.64%, 70.63%, and 51.89% respectively compared with the model group.

[0053] 5. Synergistic effect between ingredients: There is synergistic effect between the ingredients in the Chinese medicine composition of the present invention. The lack of any ingredient may affect the overall efficacy and safety of the Chinese medicine composition, emphasizing the importance of the concept of Chinese medicine compound. BRIEF DESCRIPTION OF THE DRAWINGS

[0054] Figure 1 is the uric acid level in mouse serum;

[0055] Figure 2 is the level of xanthine oxidase in liver tissue;

[0056] Figure 3 ABCG2 mRNA expression level in kidney tissue;

[0057] Figure 4 is the level of liver and kidney damage in mice, A, B, C, and D are the levels of blood urea nitrogen, blood creatinine, alanine aminotransferase, and aspartate aminotransferase, respectively. DETAILED DESCRIPTION

[0058] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0059] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0060] The raw materials used in preparing the Chinese medicine composition of the present invention are used in proportions by mass, and can be increased or decreased according to the corresponding proportions during production. For example, large-scale production can be in kilograms or tons, and small-scale production can also be in grams. The weight can be increased or decreased, but the mass ratio of the raw materials between the components follows the specified ratio.

[0061] Example 1

[0062] 1. The raw materials of the Chinese medicine composition are: 9 parts of Gastrodia elata, 3 parts of Panax notoginseng, 9 parts of lotus seed core, and 30 parts of corn silk, and the parts are all by weight.

[0063] 2. The preparation method is as follows: take the above medicinal materials, mix them, add 1L (20 times the total amount of medicinal materials) of pure water, soak for 0.5h, then boil for 0.5h, filter the extract, add 0.5L (10 times the total amount of medicinal materials) of pure water and boil for 20min to fully dissolve and extract the active ingredients, filter the extract, combine the extracts, let stand overnight, filter, and concentrate the filtrate to a clear paste by vacuum distillation to obtain the active ingredient.

[0064] Example 2

[0065] 1. The raw materials of the Chinese medicine composition are: 5 parts of Gastrodia elata, 1 part of Panax notoginseng, 5 parts of lotus seed core, and 10 parts of corn silk, and the parts are all by weight.

[0066] 2. The preparation method is as follows: mix the above medicinal materials, add 1L (16 times the total amount of medicinal materials) of pure water, soak for 0.5h, then boil for 45min, filter the extract, add 0.5L (8 times the total amount of medicinal materials) of pure water and boil for 25min to fully dissolve and extract the active ingredients, filter the extract, combine the extracts, let stand overnight, filter, and concentrate the filtrate to a clear paste by vacuum distillation to obtain the active ingredient.

[0067] Example 3

[0068] 1. The raw materials of the Chinese medicine composition are: 15 parts of Gastrodia elata, 5 parts of Panax notoginseng, 15 parts of lotus seed core, and 40 parts of corn silk, and the parts are all by weight.

[0069] 2. Preparation method: Mix the above medicinal materials, soak them in 2 L (30 times the total amount of medicinal materials) of pure water for 1 h, then steam for 60 min. After filtering the extract, add 1 L (15 times the total amount of medicinal materials) of pure water and steam for 30 min to fully dissolve and leach out the active ingredients. Filter the extract, combine the extracts, let it stand overnight, filter, and concentrate the filtrate by reduced pressure distillation to obtain the clear paste, that is, the active ingredient is obtained.

[0070] Comparative Example 1

[0071] The technical solution of Comparative Example 1 is similar to that of the example, the difference is that the corn stigma is not added to the traditional Chinese medicine composition in Comparative Example 1.

[0072] Comparative Example 2

[0073] The technical solution of Comparative Example 2 is similar to that of the example, the difference is that the lotus plumule is not added to the traditional Chinese medicine composition in Comparative Example 2.

[0074] Comparative Example 3

[0075] The technical solution of Comparative Example 3 is similar to that of the example, the difference is that the notoginseng is not added to the traditional Chinese medicine composition in Comparative Example 3.

[0076] Comparative Example 4

[0077] The technical solution of Comparative Example 4 is similar to that of the example, the difference is that the gastrodia elata is not added to the traditional Chinese medicine composition in Comparative Example 4.

[0078] Pharmacodynamic experiment

[0079] 1. Materials and methods

[0080] 1.1 Experimental materials

[0081] (1) Experimental animals: C57 / BL6 mice, purchased from Guangdong Vital River Laboratory Animal Technology Co., Ltd., animal production license number: SCXK(Yue) 2022-0063.

[0082] (2) Reagents and drugs

[0083] Modeling reagents: potassium oxonate, hypoxanthine;

[0084] Positive control group: allopurinol (Guangzhou Baiyunshan Pharmaceutical General Factory, national drug approval number: H44021492)

[0085] Blank control group: distilled water.

[0086] 1.2 Methods

[0087] (1) Animal grouping

[0088] After 1 week of adaptive feeding, SPF grade C57 / BL6 mice were randomly divided into blank control group, model group, comparative example groups 1 to 4, allopurinol comparative example group, low-dose group of Example 1, high-dose group of Example 1, and Example 2-3 groups, with 6 mice in each group.

[0089] (2) Modeling method

[0090] Male C57 / BL6 mice were given potassium oxonate (300 mg / kg) / hypoxanthine (50 mg / kg) by oral gavage once a day (in the morning) for 21 days.

[0091] (3) Method of administration

[0092] The mice in the blank control group were gavaged with an equal amount of distilled water every afternoon, the mice in the model group were gavaged with an equal amount of distilled water every morning after modeling in the afternoon, the low-dose group in Example 1 was gavaged with 8 g / kg of Chinese medicine paste every morning after modeling in the afternoon, the high-dose group in Example 1 was gavaged with 16 g / kg of Chinese medicine paste every morning after modeling in the afternoon, the allopurinol control group was gavaged with 5 mg / kg of allopurinol every morning after modeling in the afternoon, and the dosage of the other groups was consistent with that of the high-dose group in Example 1, and the samples were collected after 21 consecutive days of administration.

[0093] (4) Detection

[0094] After modeling and drug administration, the uric acid level in the serum of the experimental mice, the xanthione oxidase (XOD) in the liver tissue, and the ABCG2 renal excretion transporter in the kidney tissue were detected. Finally, the liver and kidney damage levels of the comparative examples and embodiments on the experimental mice were evaluated.

[0095] Test results

[0096] 1. Blood uric acid level

[0097] Figure 1 The changes in serum uric acid levels of mice in each group are shown. The blood uric acid level of mice in the model group was significantly higher than that in the blank control group, confirming the successful establishment of the model. The Chinese medicine compositions in both the low-dose group and the high-dose group of Example 1 can effectively reduce the blood uric acid level of mice, and the effect of the high-dose group is more significant. The blood uric acid level of mice is only 77.33 μmol / L, which is 81.53% lower than that of the model group, which is equivalent to the effect of the traditional uric acid-lowering drug allopurinol. Examples 2 to 3 can also significantly reduce the serum uric acid content of mice. The effect of Comparative Examples 1 to 4 on blood uric acid levels is not obvious, indicating that the lack of any one component alone will reduce the effect of the Chinese medicine composition.

[0098] 2. XOD content level in liver tissue

[0099] Xanthine oxidase (XOD) can oxidize hypoxanthine to xanthine, and can also directly oxidize xanthine to uric acid, promoting the formation of uric acid. Figure 2 As shown, the liver XOD activity of the model group mice was significantly higher than that of the blank control group, indicating that the increase in XOD activity under hyperuricemia was successfully simulated by a specific modeling method; Examples 1 to 3 can all reduce the XOD activity in the mouse liver, and the XOD content level can reach 23.08U / gprot, which is 17.34% lower than that of the model group, similar to the effect of the positive drug allopurinol group, further confirming the potential of the Chinese medicine composition in reducing XOD activity and thus reducing blood uric acid levels; Comparative Examples 1 to 4 have little effect on XOD activity, indicating that the lack of any one component will weaken the inhibitory effect of the Chinese medicine composition on XOD activity, thereby reducing its effect of reducing blood uric acid.

[0100] 3. ABCG2 mRNA expression level in kidney tissue

[0101] ABCG2 is a renal excretion transporter for uric acid. Compared with the blank control group, the expression level of ABCG2 in the model group mice was significantly reduced, indicating that the hyperuricemia model was successfully established. Compared with the model group, the embodiment group showed the ability to significantly increase the expression of ABCG2, and the mRNA expression level of ABCG2 could be increased by 41.09%, which was similar to the effect of the positive drug allopurinol group. This shows that the Chinese medicine composition enhances the excretion of uric acid by promoting the expression of uric acid excretion transporters, thereby helping to reduce blood uric acid levels. The results of comparative examples 1 to 4 show that the effect of the comparative example group in increasing ABCG2 expression is not as good as that of the Chinese medicine composition embodiment group with complete components, which emphasizes the importance and synergy of each component in the complete Chinese medicine composition. The lack of any one component will weaken the promotion effect of the Chinese medicine composition on the expression of the renal uric acid excretion transporter ABCG2, thereby affecting its uric acid-lowering effect.

[0102] 4. Blood urea nitrogen, alanine aminotransferase, aspartate aminotransferase, and blood creatinine levels

[0103] Increased blood urea nitrogen and creatinine levels indicate renal damage, and increased alanine aminotransferase and aspartate aminotransferase levels indicate liver damage. The model group showed a certain degree of liver and kidney damage, which is related to the inflammatory response caused by the deposition of uric acid crystals in the kidneys and liver under the state of hyperuricemia. Figure 4As shown, compared with the normal control group, the levels of blood urea nitrogen, blood creatinine, alanine aminotransferase, and aspartate aminotransferase in the model group and the comparative example 1 to 4 groups of mice were significantly increased. The Chinese medicine composition embodiments 1 to 3 can effectively reverse the increase of blood urea nitrogen, blood creatinine, alanine aminotransferase, and aspartate aminotransferase caused by high uric acid to a certain extent, compared with the model group, respectively reduced by 64.25%, 30.64%, 70.63%, and 51.89%, without causing obvious toxic damage, and effectively protecting liver and kidney tissues. Among them, the protective effect of the high-dose group of Example 1 is particularly significant, indicating that the Chinese medicine composition not only effectively reduces uric acid levels, but also has a higher safety, especially at high doses. And the high-dose group of Example 1 and the groups of Example 2 and Example 3 can restore blood urea nitrogen, alanine aminotransferase, and aspartate aminotransferase to levels comparable to the blank control group, indicating the safety of long-term administration of such uric acid-lowering Chinese medicine composition. The positive drug allopurinol group also showed a certain degree of protection, but compared with the high-dose group of the Chinese medicine composition, its safety was slightly insufficient considering the known side effects of allopurinol. The comparative group was not as effective as the complete Chinese medicine composition example group in reducing liver and kidney toxicity, which emphasized the contribution of each component in the Chinese medicine composition to the overall efficacy and safety.

[0104] Obviously, the above embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the embodiments of the present invention. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the embodiments here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. A Chinese medicine composition for lowering uric acid, characterized in that: The invention is prepared from the following raw materials in parts by weight: 5-15 parts of gastrodia elata, 1-5 parts of panax notoginseng, 5-15 parts of lotus seed core and 10-40 parts of corn silk.

2. The uric acid-lowering Chinese medicine composition according to claim 1, characterized in that: The weight ratio of the gastrodia elata to the notoginseng is 1-5:1; the weight ratio of the lotus seed core to corn silk is 1:2-8.

3. A method for preparing the uric acid-lowering Chinese medicine composition according to any one of claims 1 to 2, characterized in that: The following steps are involved: S1: Mix Gastrodia elata, Panax notoginseng, lotus seed core and corn silk and soak them in water; S2: After steaming, filter to obtain the extract; S3: adding water and boiling again, filtering to obtain the extract; S4: combining the extracts obtained from the two steamings and allowing to stand; S5: filtering, and concentrating the filtrate by vacuum distillation to obtain the uric acid-lowering Chinese medicine composition.

4. The method for preparing the uric acid-lowering Chinese medicine composition according to claim 3, characterized in that: The amount of water added in S1 and S3 is 8 to 30 times the total weight of Gastrodia elata, Panax notoginseng, lotus seed core and corn silk.

5. The method for preparing the uric acid-lowering Chinese medicine composition according to claim 3, characterized in that: The soaking time in S1 is greater than 0.5 h.

6. The method for preparing the uric acid-lowering Chinese medicine composition according to claim 3, characterized in that: The cooking time in S2 is greater than 0.5 h.

7. The method for preparing the uric acid-lowering Chinese medicine composition according to claim 3, characterized in that: The cooking time in S3 is greater than 20 min.

8. Use of the uric acid lowering Chinese medicine composition according to any one of claims 1 to 2, characterized in that: Used for preparing uric acid-lowering drugs.

9. A uric acid-lowering drug, characterized in that: The composition is prepared from the uric acid lowering Chinese medicine composition according to any one of claims 1 to 2.

10. The uric acid-lowering drug according to claim 9, characterized in that: The Chinese medicine preparation is an oral preparation, including tablets, capsules, syrups, extracts, and mixtures.

Images